---
title: "LSL Pharma Group Grants 960,000 Stock Options to Directors and Employees"
description: "LSL Pharma Group Inc. has granted 960,000 stock options to its non-executive directors, executives, and employees as part of their compensation. The options have an exercise price of CAD $0.52 per sha"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/274717860.md"
published_at: "2026-02-03T21:50:04.000Z"
---

# LSL Pharma Group Grants 960,000 Stock Options to Directors and Employees

> LSL Pharma Group Inc. has granted 960,000 stock options to its non-executive directors, executives, and employees as part of their compensation. The options have an exercise price of CAD $0.52 per share and a ten-year term. Non-executive directors’ options vest immediately, while those for executives and employees will vest over three years, subject to a four-month hold period.

LSL Pharma Group Inc. has granted a total of 960,000 stock options to its non-executive directors, executives, and employees as part of their compensation. The options have an exercise price of CAD $0.52 per share and a ten-year term. While non-executive directors’ options vest immediately, those granted to executives and employees will vest over three years. All options are subject to a four-month hold period. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LSL Pharma Group Inc. published the original content used to generate this news brief via CNW (Ref. ID: C1919) on February 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [LBRX.US - LB Pharmaceuticals](https://longbridge.com/en/quote/LBRX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| LB Pharmaceuticals Raises $100 Million in Private Placement with Shares and Pre-Funded Warrants Issued | LB Pharmaceuticals Inc. has raised $100 million through a private placement, issuing pre-funded warrants for 1,417,107 s | [Link](https://longbridge.com/en/news/274977918.md) |
| Roth MKM Keeps Their Buy Rating on LB Pharmaceuticals, Inc. (LBRX) | Roth MKM analyst Boobalan Pachaiyappan has maintained a Buy rating on LB Pharmaceuticals, Inc. (LBRX) with a price targe | [Link](https://longbridge.com/en/news/273861458.md) |
| LB Pharmaceuticals Launches Phase 2 Trial of LB-102 for Bipolar Depression | LB Pharmaceuticals Inc. has launched a Phase 2 clinical trial, ILLUMINATE-1, to assess the efficacy and safety of LB-102 | [Link](https://longbridge.com/en/news/273704681.md) |
| LB Pharmaceuticals, Inc. (LBRX) Receives a New Rating from Roth MKM | LB Pharmaceuticals, Inc. (LBRX) has received a Buy rating and a price target of $31.00 from Roth MKM analyst Boobalan Pa | [Link](https://longbridge.com/en/news/272027134.md) |
| LB Pharmaceuticals Grants Chief Commercial Officer Stock Options Valued at $21.36 Per Share | LB Pharmaceuticals Inc. has granted Kaya Pai Panandiker, the new Chief Commercial Officer, an option to purchase 195,000 | [Link](https://longbridge.com/en/news/269290802.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.